Evidence map›Paper›PMID 42327170›Full record

ArticlebioRxiv : the preprint server for biology2026

Identification of the complete pathway for conversion of bilirubin to urobilinogen by human gut bacteria.

Baylee J Russell, Erik Hasenoehrl, Victoria M Marando, Joy Lu, Jessica M Chen, Michael J James, Mudita Goyal, Suzanne Walker, Seth Rakoff-Nahoum, Marco Jost

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Baylee J RussellDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5284-3809
Erik HasenoehrlDivision of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-1507-741X
Victoria M MarandoDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3557-5838
Joy LuDivision of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-0442-3743
Jessica M ChenDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.ORCID 0009-0006-2902-7065
Michael J JamesDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.
Mudita GoyalDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.
Suzanne WalkerDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0545-914X
Seth Rakoff-NahoumDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3233-0675
Marco JostDepartment of Microbiology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1369-4908

Funding

Discovery and characterization of new bacterial cell wall targets and inhibitors to treat resistant infectionsR01AI148752 · NIAID · HARVARD MEDICAL SCHOOL · PI Daniel Kahne, Suzanne Walker · 2020 to 2026
$5.5M
Immunological and Microbial Mechanisms in Food AllergyR01AI126915 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Talal Amine Chatila, Seth Rakoff-Nahoum · 2017 to 2026
$4.9M
Programmable benchtop bioreactors for scalable eco-evolutionary dynamics of the human microbiomeR01AI171100 · NIAID · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI KHALIL, AHMAD SAMIR, RAKOFF-NAHOUM, SETH · 2022 to 2025
$4.1M
Targeting microbial dysbiosis in Food Allergy to restore toleranceR01AI158814 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI CHATILA, TALAL AMINE, RAKOFF-NAHOUM, SETH · 2021 to 2025
$3.0M
Positive Selection as a Host Mechanism to Control the MicrobiomeDP2GM136652 · NIGMS · BOSTON CHILDREN'S HOSPITAL · PI RAKOFF-NAHOUM, SETH · 2019 to 2019
$2.7M
Capturing, quantifying, and understanding combinatorial effects in small molecule signalingDP2GM154152 · NIGMS · HARVARD MEDICAL SCHOOL · PI Marco Jost · 2023 to 2026
$2.5M
Leveraging glycan-metabolite interactions to shape structure and function of the gut microbiomeR01DK138023 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Seth Rakoff-Nahoum · 2024 to 2026
$2.0M
Research Training in Gastrointestinal and Hepatic DiseasesT32DK135449 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI Jessica R. Allegretti · 2023 to 2026
$1.7M
Deciphering the logic of glycolipid signaling at the host-microbiome interfaceR00GM130964 · NIGMS · HARVARD MEDICAL SCHOOL · PI JOST, MARCO · 2021 to 2023
$747k
NIAID NIH HHS R01 AI126915NIAID NIH HHS R01 AI148752NIAID NIH HHS R01 AI158814NIAID NIH HHS R01 AI171100NIDDK NIH HHS R01 DK138023NIDDK NIH HHS T32 DK135449NIGMS NIH HHS DP2 GM136652NIGMS NIH HHS DP2 GM154152NIGMS NIH HHS R00 GM130964
6 · The paper itself

Abstract

Bilirubin, the predominant product of heme catabolism in mammals, enters the intestine via the hepatobiliary system and subsequently is metabolized by the gut microbiome. This process consumes bilirubin and generates multiple downstream derivatives, such as urobilinogen and stercobilinogen. Levels of bilirubin and its derivatives are associated with susceptibility to inflammatory and metabolic disorders, but the microbial species and enzymes that metabolize bilirubin have remained largely unknown. Here, demonstrate that metabolism of bilirubin to urobilinogen requires two separate reactions that can occur in either order and identify novel enzymes and pathway intermediates required for conversion. We find that bilirubin reductase (BilR), an enzyme that was recently discovered and proposed to convert bilirubin to urobilinogen, is specific for reducing the methine bridges of bilinoids, converting bilirubin to the novel intermediate divinylurobilinogen and mesobilirubin to urobilinogen. Using transcriptomic profiling, we identify the bilinoid vinyl reductase (BilV) responsible for reducing the vinyl groups of bilirubin and divinylurobilinogen. BilV is a flavin-dependent oxidoreductase of the Old Yellow Enzyme (OYE) superfamily with a broad distribution across human gut bacteria that overlaps with but does not completely mirror the distribution of BilR. These findings establish the complete pathway for bacterial conversion of bilirubin to urobilinogen, enabling defined studies to interrogate how this metabolism contributes to human health and disease.

Identifiers

PMID42327170
PMCPMC13278186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.